Merck & Co., Inc. (MRK) — closed signal from September 21, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 20, 2025.
Predicted vs. what happened
What happened
Reached its target in 54 days.
The thesis — published September 21, 2025
Merck's share price has pulled back, but new FDA approval for an easier, under-the-skin version of Keytruda across most solid tumors adds a practical boost. Easier dosing can keep patients on Merck's medicine longer, supporting steady sales. The dividend helps limit deeper dips. If the stock moves back above 85, it would signal the slide is easing and could set up a multi-month return toward its prior range over the next few months.
Primary drivers
- FDA cleared an easier under-the-skin Keytruda shot, broad availability
- Stock fell hard recently and looks due for a bounce as sellers fade
- Reliable dividend can attract buyers and help soften sharp pullbacks
- Strong belief in cancer drug growth keeps long-term story attractive
How it played out
MRK: target reached in 54 days
Lyra published MRK at $80.82 on September 21, 2025, with expected growth of 16% toward $92.96. The thesis pointed to FDA clearance for an easier under-the-skin Keytruda shot, a hard recent pullback, dividend support, and continued belief in cancer drug growth.
Inside the window, MRK reached the target in 54 days. It later peaked at $104.94 on November 25, with a peak gain of 29.8%. The stock ended the window at $101.09. The thesis played out, and the move went past the published target.
What happened during the window
On October 30, 2025, Merck reported third-quarter sales of $17.28 billion and adjusted earnings per share of $2.58, according to Investor's Business Daily. The same report said Keytruda sales rose 10% to $8.14 billion, while Gardasil sales fell 24%.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.